Chronic recombinant equine somatotropin (eST) administration does not affect aerobic capacity or exercise performance in geriatric mares

Effect of omeprazole on markers of performance in gastric ulcer-free Standardbred horses

REASONS FOR PERFORMING STUDY

A large percentage of performance horses develop gastric ulcers and many of those horses are treated with omeprazole. Unfortunately, no data have been published on the effects of the drug on markers of performance in animals without ulcers.

HYPOTHESIS

Omeprazole would alter markers of aerobic and anaerobic performance.

METHODS

Ten unfit, healthy, ulcer free, Standardbred mares were administered either control (CON; oral apple sauce, 20 ml) or omeprazole (OP; oral paste, 4 mg/kg bwt s.i.d.) in a random crossover fashion with the investigators blind to the treatment. Treatments were administered for 7 days prior to performing an incremental exercise test (GXT) on a high-speed treadmill. Endoscopic examinations were performed just prior to the trial to verify that the mares were ulcer-free. During the GXT, the mares ran on a treadmill up a 6% grade to measure maximal oxygen consumption (VO2max), run time (RT), velocity at VO2max, maximal velocity (Vmax), packed cell volume (PCV), plasma lactate concentration (LA) and plasma protein concentration (TP). Measurements were recorded at rest, at the end of each 1 min step of the GXT and at 2 and 5 min post GXT. Data were analysed using ANOVA for repeated measures and t tests for paired comparisons.

RESULTS

There was no effect (P>0.05) of omeprazole on VO2max; velocity at VO2max; RT; Vmax; 2 min recovery plasma LA. Nor were there any changes (P>0.05) in the relationship between treadmill speed and VO2, PCV, TP, or plasma LA.

CONCLUSIONS

Omeprazole does not appear to improve physiological markers of performance in healthy, ulcer free horses.

POTENTIAL RELEVANCE

These data may benefit various authorities responsible for deciding administration and timing policies of omeprazole as well as clinicians and horse owners.

Plasma β-endorphin, cortisol and immune responses to acute exercise are altered by age and exercise training in horses

REASONS FOR PERFORMING STUDY

Ageing appears to affect immune and neuroendocirne function in horses and response to acute exercise. No studies have examined the combined effects of training and ageing on immune and neuroendocirne function in horses.

HYPOTHESIS

To ascertain whether training and age would affect the plasma beta-endorphin (BE) and cortisol (C) as well as immune function responses to acute exercise in Standardbred mares.

METHODS

Graded exercise tests (GXT) and simulated race tests (SRT) were performed before and after 12 weeks training at 60 % HRmax. BE and C were measured at rest and at 5, 10, 20, 40, 60 and 120 min post GXT. Leucocyte cell number, CD4+ and CD8+ lymphocyte subsets, and mitogen stimulated lymphoproliferative response (LPR), were measured in jugular blood before and after the SRTs.

RESULTS

Cortisol rose by 5 min post GXT in young (Y) and middle-age (MA) mares (P<0.05) and remained elevated until 40 and 60 min post GXT, respectively during both pre- and post training GXT. There was no rise in C in old (0) mares after either GXT (P>0.05). Pretraining BE rose (P<0.05) by 5 min post GXT in all mares. After training, BE was higher in Y and O vs. MA (P<0.05) at 5 min post GXT. Post training BE was higher at 5 min post GXT in Y and O vs. pretraining (P<0.05). After SRT, lymphocyte number rose in all mares (P<0.05); however, lower lymphocyte numbers (P<0.05) were seen in MA vs. Y and O vs. MA (P<0.05). The O had reduced LPR to Con A and PHA stimulation (P<0.05) compared to Y and MA after the SRT after both pre- and post training SRT. LPR to PWM was lower (P<0.05) in O vs. Y and MA after the pretraining SRT. Training caused an increase in resting LPR to PWM in MA only (P<0.05).

CONCLUSION

Both age and training altered the plasma beta-endorphin and cortisol responses as well as and immune responses to acute exercise.

POTENTIAL RELEVANCE

This study provides important information on the effects of ageing and training that will aid in the management and care of an increasing number of active older horses.

Low dose exogenous erythropoietin elicits an ergogenic effect in Standardbred horses

REASONS FOR PERFORMING STUDY

Recombinant human erythropoietin (rhuEPO) causes an increase in red blood cell production and aerobic capacity in other species; however, data are lacking on effects in the horse.

HYPOTHESIS

This study tested the hypothesis that rhuEPO administration would alter red cell volume (RCV), aerobic capacity (VO2max) and indices of anaerobic power.

METHODS

Eight healthy, unfit mares accustomed to the laboratory and experimental protocols were randomly assigned to either a control (CON, n = 4; 3 ml saline 3 times/week for 3 weeks) or EPO group (EPO, n = 4, 50 iu/kg bwt rhuEPO/3 ml saline 3 times/week for 3 weeks). Exercise tests (GXT) were performed on a treadmill (6% incline), 1 week before and 1 week after treatment. The GXT started at 4 m/sec, with a 1 m/sec increase every 60 sec until the horse reached fatigue. Oxygen uptake was measured via an open flow indirect calorimeter. Blood samples were collected before, during (each step) and 2 and 15 min post GXT to measure packed cell volume (PCV), haemoglobin concentration (Hb), blood lactate concentration (LA) and plasma protein concentration (TP). Plasma volume (PV) was measured using Evans Blue dye. Blood volume (BV) and RCV were calculated using PCV from the 8 m/sec step of the GXT.

RESULTS

There were no alterations (P>0.05) in any parameters in CON horses. By week 3, EPO produced increases (P<0.05) in resting PCV (37 +/- 2 vs. 51 +/- 2) and Hb (37%). RCV (26%) and VO2max (19%) increased, but BV did not change (P>0.05) due to decreased PV (-11%, P<0.05). There was a significant increase in velocity at VO2max and LApeak for horses treated with rhuEPO and substantial decrease (P<0.05) in VO2 recovery time when the pretreatment GXT was compared to the post treatment GXT. No differences (P<0.05) were detected for TP, VLA4, run time or Vmax.

CONCLUSIONS

Low dose rhuEPO administration increases RCV and aerobic capacity without altering anaerobic power.

POTENTIAL RELEVANCE

This study demonstrates that rhuEPO enhances aerobic capacity and exercise performance, a question relevant to racing authorities.

Veterinary medicines and competition animals: the question of medication versus doping control

In racing and other equine sports, it is possible to increase artificially both the physical capability and the presence of a competitive instinct, using drugs, such as anabolic steroids and agents stimulating the central nervous system. The word doping describes this illegitimate use of drugs and the primary motivation of an equine anti-doping policy is to prevent the use of these substances. However, an anti-doping policy must not impede the use of legitimate veterinary medications and most regulatory bodies in the world now distinguish the control of illicit substances (doping control) from the control of therapeutic substances (medication control). For doping drugs, the objective is to detect any trace of drug exposure (parent drug or metabolites) using the most powerful analytical methods (generally chromatographic/mass spectrometric techniques). This so-called "zero tolerance rule" is not suitable for medication control, because the high level of sensitivity of current screening methods allows the detection of totally irrelevant plasma or urine concentrations of legitimate drugs for long periods after their administration. Therefore, a new approach for these legitimate compounds, based upon pharmacokinetic/pharmacodynamic (PK/PD) principles, has been developed. It involves estimating the order of magnitude of the irrelevant plasma concentration (IPC) and of the irrelevant urine concentration (IUC) in order to limit the impact of the high sensitivity of analytical techniques used for medication control. The European Horserace Scientific Liaison Committee (EHSLC), which is the European scientific committee in charge of harmonising sample testing and policies for racehorses in Europe, is responsible for estimating the IPCs and IUCs in the framework of a Risk Analysis. A Risk Analysis approach for doping/medication control involves three sequential steps, namely risk assessment, risk management, and risk communication. For medication control, the main task of EHLSC in the risk management procedure is the establishment of harmonised screening limits (HSL). The HSL is a confidential instruction to laboratories from racing authorities to screen in plasma or urine for the presence of drugs commonly used in equine medication. The HSL is derived from the IPC (for plasma) or from the IUC (for urine), established during the risk assessment step. The EHSLC decided to keep HSL confidential and to inform stakeholders of the duration of the detection time (DT) of the main medications when screening is performed with the HSL. A DT is the time at which the urinary (or plasma) concentration of a drug, in all horses involved in a trial conducted according to the EHSLC guidance rules, is shown to be lower than the HSL when controls are performed using routine screening methods. These DTs, as issued by the EHSLC (and adopted by the Fédération Equestre Internationale or FEI) provide guidance to veterinarians enabling them to determine a withdrawal time (WT) for a given horse under treatment. A WT should always be longer than a DT because the WT takes into account the impact of all sources of animal variability as well as the variability associated with the medicinal product actually administered in order to avoid a positive test. The major current scientific challenges faced in horse doping control are those instances of the administration of recombinant biological substances (EPO, GH, growth factors etc.) having putative long-lasting effects while being difficult or impossible to detect for more than a few days. Innovative bioanalytical approaches are now addressing these challenges. Using molecular tools, it is expected in the near future that transcriptional profiling analysis will be able to identify some molecular "signatures" of exposure to doping substances. The application of proteomic (i.e. the large scale investigation of protein biomarkers) and metabolomic (i.e. the study of metabolite profiling in biological samples) techniques also deserve attention for establishing possible unique fingerprints of drug abuse.

Effect of orange peel and black tea extracts on markers of performance and cytokine markers of inflammation in horses

This study tested the hypothesis that orange peel (O) and decaffeinated black tea (T) extracts would alter markers of exercise performance as well as exercise-induced mRNA expression for the inflammatory cytokines IL-6, TNF-alpha and IFN-gamma. Nine healthy, unfit Standardbred mares (age: 10±4years, ∼450kg) were assigned to three treatment groups in a randomized crossover design where each horse was administered one of the following; placebo (O; 21 water), black tea extract in water (T; 21) or orange peel extract in water (W; 21), via a nasogastric tube. One hour later the horses completed an incremental graded exercise test (GXT) on a treadmill at a fixed 6% grade with measurements and blood samples obtained at rest, at the end of each 1min step of the GXT and at 2 and 5min post-GXT. An additional set of blood samples for Polymerase Chain Reaction (PCR) measurements of mRNA was obtained before exercise and at 5 and 30min and 1, 2, 4 and 24h post-GXT. The GXTs were conducted between 0700 and 1200h not less than 7days apart. There were no differences (P>0.05) in VO2max, respiratory exchange ratio, run time, velocity at VO2max, core body temperature, haematocrit, creatine kinase (CK), plasma lactate concentrations, HR, right ventricular pressure (RVP) or pulmonary artery pressure (PAP) across treatments. A major finding was that orange peel extract significantly reduced post-exercise VO2 recovery time (W = 112±7, O = 86±6, and T = 120±11s). There was a significant difference in plasma total protein concentration (TP) in the O runs compared with water and T. TNF-alpha mRNA expression was lower in the T runs compared with water and O trials. IFN-gamma mRNA expression levels appeared to be lower in both the T and O extract runs compared with the water trials. The mRNA expression of IL-6 was unaltered across treatment groups. These data suggest that orange peel and black tea extracts may modulate the cytokine responses to intense exercise. Orange peel extract reduced post-exercise recovery time and may potentially enhance the ability of horses to perform subsequent bouts of high-intensity exercise.

Effect of seven common supplements on plasma electrolyte and total carbon dioxide concentration and strong ion difference in Standardbred horses subjected to a simulated race test

This study used a randomized crossover design, with investigators blind to the treatment given, to test the hypothesis that seven commercially available electrolyte supplements would alter plasma concentrations of Na+, K+, Cl−, lactate, total protein (TP) and total carbon dioxide (tCO2) as well as plasma strong ion difference (SID) and haematocrit (HCT). Ten unfit Standardbred mares (∼450 kg, 4–9 years) completed a series of simulated race exercise tests (SRT) during which venous blood was collected at five sampling intervals (prior to receiving electrolyte treatment, prior to the SRT, immediately following exercise and at 60 and 90 min post-SRT). Plasma electrolyte and tCO2 concentrations were measured in duplicate using a Beckman EL-ISE electrolyte analyser. No difference (P>0.05) between treatments was detected at any of the five sampling intervals for plasma [Na+], [K+], [Cl−] or [tCO2]. Similarly, no significant difference was detected between treatments across each of the five sampling intervals for plasma SID, HCT or TP concentration. There were differences (P<0.05) in plasma [Na+], [K+] and [tCO2] (as well as plasma SID, HCT, and TP concentration) in the immediately post-SRT samples that were attributable to the physiological pressures associated with acute exercise. No differences (P>0.05) were detected between treatments across the pre-electrolyte and pre-SRT sampling intervals for plasma lactate concentration. There was, however, a significant time by treatment interaction during the 0, 60 and 90 min post-SRT sampling intervals for this parameter. The electrolyte supplements featured in this investigation did not affect either plasma tCO2 concentration or SID; however, this result does not rule out the potential for other supplements, especially those containing alkalinizing ingredients, to exert an effect that could push a horse towards threshold values.

Myosin heavy chain profiles and body composition are different in old versus young Standardbred mares

There are limited data on age-related changes in body composition or skeletal muscle in the horse. Therefore, the purpose of this study was to investigate any differences in muscle myosin heavy chain (MHC) and body composition associated with aging. Twenty-three young (4-8 years) and eight old (20+ years) unfit Standardbred mares were evaluated. Rump fat thickness was measured using B-mode ultrasound and per cent body fat (% fat) was calculated. Needle muscle biopsies were obtained from right gluteus medius muscle. MHC composition was determined via sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Three MHC isoforms were subsequently identified as type I, type IIA, and type IIX and quantified using a scanning and densometric system. There were no significant differences (p>0.05) between old and young mares in fat (%) (19.0+/-6.4 vs 20.5+/-5.4), fat mass (kg) (102.3+/-39.9 vs 106.9+/-37.1), or body weight (kg) (529.4+/-34.9 vs 512.7+/-57.7). However, the old mares had significantly (p<0.05) greater lean body mass than the young mares (427.1+/-24.5 vs 405.7+/-37.9). Aged mares had significantly (p<0.05) less type I (7.8+/-2.9% vs 12.1+/-4.4%) and IIA (27.8+/-7.1% vs 36.1+/-9.5%) fibres than the young group but more type IIX (64.6+/-4.7% vs 51.8+/-11.1%). The MHC data are consistent with the age-related changes seen in other species.

Recombinant equine growth hormone administration: effects on synovial fluid biomarkers and cartilage metabolism in horses

REASONS FOR PERFORMING STUDY

Recombinant equine growth hormone (reGH) has recently been evaluated for effects on body condition and wound healing. It has the potential to influence articular cartilage via stimulation of IGF-1.

OBJECTIVES

To investigate effects of administration on synovial joint metabolism.

METHODS

Six mature horses were given 20 microg/kg bwt reGH daily for 8 weeks by i.m. injection. Three control horses were injected with sterile water. Serum and synovial fluid samples were collected at 6, 8, 11 and 16 weeks for GH and IGF-1 assays. Articular cartilage harvested at week 16 was evaluated by Western analysis using monoclonal antibodies BC-13, BC-4, 8-A-4 and CH-3.

RESULTS

Concentrations of IGF-1 in serum and synovial fluid were significantly elevated (P < 0.05) at 6 and 8 weeks in the reGH group. Glycosaminoglycan concentrations in synovial fluid were significantly less than controls at these time points, suggesting that reGH may modulate proteoglycan metabolism in articular cartilage. In the reGH group, there were not any alterations in synovial fluid content of 3B3(-) epitope or aggrecan metabolite, or in aggrecan or link protein catabolites retained within cartilage, that might be expected with development of osteoarthritis.

CONCLUSIONS

Intramuscular administration of reGH may be a more efficient means of delivery of IGF-1 to joints for cartilage resurfacing initiatives.

POTENTIAL RELEVANCE

We found no alterations in cartilage metabolism indicative of development of osteoarthritis.

Exercise physiology of the older horse

Surveys indicate that up to 15% of the equine population in the United States is older than 20 years of age, with many of these animals performing various athletic activities well into their 20s. As is the case with their human counterparts, these geriatric equine athletes have the ability to continue to perform in athletic events. Unfortunately, many horse owners continue to train their active older animals using exercise training protocols that, although appropriate for a younger animal, may not be appropriate for the older equine athlete. Studies in aged human beings have led to a fine-tuning of exercise prescription for the older human athlete so as to prevent the adverse and potentially dangerous effects of excessive work. Published results have led to new and improved programs to promote fitness for the growing population of older adults. Unfortunately, limited data exist regarding the exercise capacity of the aged horse. Future studies on the effects of aging on exercise capacity in equine athletes need to take a few major directions. One question to be answered is at what age does physiologic function first begin to decline in the horse? In human beings, this age varies with training, but noticeable changes in aerobic capacity are first seen in 40- to 50-year-olds. Second, data are needed to determine what levels of exercise enhance the health and well-being of the older horse without harm. Lastly, studies are needed to determine the physiologic mechanisms associated with the onset of aging-induced decreases in physiologic function in the horse. The ultimate goal of all these studies should be to adjust exercise levels to meet the needs of the growing population of athletically active older equine athletes.

Effects of somatotropin and training on indices of exercise capacity in Standardbreds

The recent availability of recombinant equine somatotropin (eST) has led to concern about its use as an ergogenic aid in racehorses. This study was undertaken to investigate the changes in exercise capacity in maturing horses in a training programme, and to assess whether eST is an ergogenic aid to this group. We tested the hypothesis that the combination of training and eST, compared to training alone, would further improve exercise capacity in maturing Standardbreds, by virtue of ST's anabolic effects and potential to enhance cardiac function, circulating fluid volume and red cell mass. Twelve, untrained Standardbreds (mean +/- s.d. 20.7 +/- 1.1 months) were paired according to similar bodyweight and then assigned randomly to treatment or control group. The horses underwent a 12 week treadmill training programme. Methionyl eST (10 microg/kg for the first 7 days, then 20 microg/kg) was administered once daily, i.m., for 42 consecutive days (Weeks 4 to 9 inclusive) to 6 horses in the treatment group. All horses performed a standardised maximal exercise test to fatigue at Weeks 0, 3, 6, 9, and 12. During each exercise test VO2, VCO2, plasma lactate concentrations ([La]), heart rates, blood volume and total run time were measured. There was no significant effect of eST administration on VO2max, V200, V(LA4), LA9, red cell volume (RCV), plasma volume (PV), or run time to fatigue. Combining the data for all horses, training significantly altered the VO2max (mean +/- s.d. 98.2 +/- 11.1 ml/kg/min in Week 0 to 117.6 +/- 4.8 ml/kg/min in Week 12), V(LA4) (5.1 +/- 0.8 m/s to 7.4 +/- 1.0 m/s), LA9 (12.7 +/- 3.9 mmol/l to 7.1 +/- 1.9 mmol/l), RCV (46.3 +/- 4.7 ml/kg to 63.5 +/- 5.0 ml/kg), PV (46.0 +/- 4.8 ml/kg to 57.0 +/- 6.3 ml/kg), and run time to fatigue (431.8 +/- 30.9 to 490.2 +/- 30.5 s), but not V200 (5.0 +/- 0.5 m/s to 5.2 +/- 1.1 m/s). The administration of eST to young Standardbred horses in training did not significantly improve their exercise capacity or indices of fitness. However, these maturing horses demonstrated a rapid physiological response to training exercise. Further research is required to determine the relationship between exercise capacity and ST in the horse.

Plasma aldosterone concentration and renal sodium excretion are altered during the first days of training

The purpose of the present study was to determine whether the training-induced hypervolaemic response seen in the horse is associated with aldosterone-mediated renal mechanisms affecting sodium conservation during the first days of training. Five healthy, Standardbred mares (weight 450-500 kg, age 4-8 years) that were unfit, but accustomed to running on the treadmill, were used to test the hypothesis that repeated submaximal exercise would alter plasma aldosterone (ALDO) concentration and renal excretion of electrolytes in horses within the first 3 days of training. The experiment consisted of a 2 week housing equilibration period followed by a 1 week control period and a 3 day exercise training period (30 min/day at 60% VO2max). During control, ALDO and renal fluid and electrolyte losses were measured for 24 h on 3 separate days. Renal function (urine volume [UV], 24 h excretion of Na+, K+ and Cl- [UNA+ V, UK+ V, UCl- V], clearance of Na+ [CNa+], K+ [CK+] and Cl- [CCl-], creatinine [CCr], osmotic substances [Cosm], and solute-free water [FWC], and the fractional excretion of Na+, K+ and Cl-) and ALDO were measured for an additional 3 consecutive days during the training period. There were no differences (P>0.05) in any variable during the control period. Plasma volume increased (+18.7%, P<0.05) after 3 days of training. During training, there were no significant changes in plasma osmolality, electrolyte concentrations or CCr. Training caused decreases (P<0.05) in UV (-30%), UNA+ V (-73%), UK+ V, (-55%) and UCl- V (-70%). Training also caused decreases (P<0.05) in Cosm (-30%), through decreases in CNa+ (-60%), CK+ (-60%), and CCl- (-66%). Interestingly, FWC increased (+30%, P<0.05), whereas, there were significant decreases in the fractional excretion of Na+ (-59%), K+ (-48%) and Cl- (-60%). Training caused substantial elevations in both pre-exercise (967%, P<0.05) and postexercise (+3013%, P<0.05) plasma ALDO concentrations suggesting an increase in both basal levels and the responsiveness to acute exercise. Together, these observations suggest that mechanisms affecting tubular conservation of electrolytes contribute to the early response to training. However, it is also concluded that renal mechanisms appear to be only part of the mechanism for conserving sodium and water intake as well as training-induced changes in gastrointestinal mechanisms affecting electrolyte and water balance.

Effects of ageing and training on maximal heart rate and VO2max

The purpose of this study was to test the hypotheses that ageing would result in a decline in maximal heart rate (HRmax) and maximal aerobic capacity (VO2max) and, secondarily, that those effects would be reversible with training. Eighteen, healthy, unfit Standardbred mares representing 3 age groups: young (Y = mean +/- s.e. 6.8 +/- 0.4 years, n = 6); middle-aged (MA = 15.2 +/- 0.4 years, n = 6); and old (O = 27.0 +/- 0.2 years, n = 6) were used. HRmax, VO2max and oxygen pulse at VO2max (OPmax) and the velocities producing HRmax (VHRmax) and VO2max (VVO2max) were measured during pretraining and post-training incremental exercise tests (GXT). During training, mares exercised 3 days/week (Weeks 1-8) and 4 days/week (Weeks 9-12) at a submaximal intensity (approximately 60% HRmax) for approximately 30 min/day. There were no differences (P>0.05) between Y and MA, before (218 +/- 2 vs. 213 +/- 3 beats/min; 116 +/- 3 vs. 109 +/- 3 ml/kg bwt/min; 0.55 +/- 0.01 vs. 0.52 +/- 0.02 ml/kg/beat; 9.0 +/- 0.3 vs. 9.3 +/- 0.2 ms; 8.8 +/- 0.2 vs. 8.8 +/- 0.2 m/s) or after training (224 +/- 2 vs. 218 +/- 2 beats/min; 131 +/- 3 vs. 120 +/- 2 ml/kg bwt/min; 0.58 +/- 0.01 vs. 0.55 +/- 0.01 ml/kg/beat; 10.5 +/- 0.2 vs. 9.5 +/- 0.1 ms; 10.6 +/- 0.2 vs. 9.5 +/- 0.1 m/s) for HRmax, VO2max, OPmax, VHRmax or VVO2max, respectively. Old horses had lower HRmax, VO2max and OPmax and reached them at lower velocities compared to Y and MA (P<0.05), both before (193 +/- 3 beats/min; 83.2 +/- 2.0 ml/kg bwt/min; 0.43 +/- 0.01 ml/kg/beat; 7.8 +/- 0.1 m/s; 7.2 +/- 0.1 m/s) and after training (198 +/- 2 beats/min; 95 +/- 2 ml/kg bwt/min; 0.48 +/- 0.01 ml/kg/beat; 8.2 +/- 0.2 m/s; 8.0 +/-0.2 m/s). Training did not alter HRmax in any age group (P>0.05) but did cause increases in VO2max, OPmax and VVO2max for all groups (P<0.05). Interestingly, training increased VHRmax only in Y (P<0.05). These data demonstrate that there is a reduction in HRmax, VO2max, OPmax, VHRmax and VVO2max in old horses, and that training can partially reverse some effects of ageing.

The endocrine system and the challenge of exercise

Fine-tuning of the response to exercise that lasts longer than a few seconds is reliant on the regulation of several key variables governing the cardiopulmonary, vascular, and metabolic response to exercise. This type of integrative response requires communication between organ systems that relies on the secretion of endocrine and paracrine substances by one tissue or organ that are transported remotely to other tissues or organs to evoke a response to adjust to the disturbance.

Endothelin response during and after exercise in horses

The objective of the present study was to measure plasma endothelin-1 (ET-1) at rest and during exercise in the horse. Six healthy, Standardbred and Thoroughbred mares (5.3+/-0.8 years; 445.2+/-13.1 kg) which were unfit, but otherwise accustomed to running on the treadmill, were used in the study. Plasma ET-1 concentrations were measured using a commercially available radioimmunoassay kit. Horses performed three trials: a standing control (CON) trial where blood was collected from the jugular vein every minute for 5 min; a graded exercise test (GXT) where blood samples were collected at the end of each 1 min step of an incremental exercise test; and a 15 min submaximal (60% VO(2max)) steady-state exercise test (SST) where blood samples were collected 1 min before, immediately after, and at 2 min, 10 min and 20 min post-exercise. Plasma ET-1 concentration did not change (P>0.05) during the CON trial where it averaged 0.18+/- 0.03 pg/mL (mean+/-SE). Surprisingly, plasma ET-1 concentration did not change during the GXT trial where it averaged 0.20+/-0.03 pg/mL. There were no differences between the mean concentrations obtained in either trial (P>0.05). Plasma ET-1 concentrations were, however, significantly elevated (P<0.05) immediately following exercise and at 2 min post-exercise in the SST. Post-exercise plasma ET-1 concentrations returned to baseline (P>0.05) by 10 min of recovery. Together, these data may suggest that ET-1 concentrations are altered in response to an exercise challenge.

The effects of bovine recombinant growth hormone administration on insulin-like growth factor-I and the haemopoietic system in thoroughbred geldings

The effect of intramuscularly administered recombinant bovine growth hormone (rbGH) on insulin-like growth factor-I (IGF-I) and white and red blood cell indices was studied in Thoroughbred geldings. An insulin-like growth factor binding protein (IGFBP)-blocked radioimmunoassay was modified and validated for the measurement of IGF-I in equine blood plasma. Baseline values of IGF-I and blood indices were determined over a 48 h period and then a single dose of 5 microg/kg, 10 microg/kg or 50 microg/kg of rbGH was administered. Insulin-like growth factor-I levels increased in a dose-dependent manner, with the highest values between 12 h and 24 h. The highest dose (50 microg/kg) yielded the greatest IGF-I response with a 90.2+/-10.8% increase at 24 h. White blood cell count increased following the three doses of rbGH with the highest white blood cell count at 12 h after the 50 microg/kg dose. Haemoglobin was significantly increased at 24 h (P< 0.05), when values following doses of 10 microg/kg and 50 microg/kg were significantly greater than after the vehicle or the dose of 5 microg/kg. Red blood cell count was not affected by any of the rbGH doses. These results indicated that rbGH is biologically active in the horse and that rbGH at a dose rate of 10 microg/kg or more could be used therapeutically.

Endocrine response to exercise in young and old horses

Six young (mean + s.e., 5.3 +/- 0.8 years, 445 +/- 13 kg bwt) and 6 old (22.0 +/- 0.4 years, 473 +/- 18 kg bwt) Standardbred and Thoroughbred mares were used to test the hypothesis that age would alter the endocrine response to exercise. All of the mares were unconditioned but accustomed to the laboratory, to standing quietly and running on a treadmill, and to the standardised incremental exercise test (SET) used in the experiment. Two weeks prior to the experiment, each horse underwent a SET to determine maximal oxygen uptake (VO2max) and the speeds to be used in the actual experiment. A second graded exercise test (GXT) was performed without instrumentation for the measurement of plasma renin activity (PRA) and the plasma concentrations of atrial natriuretic peptide (ANP), arginine vasopressin (AVP), aldosterone (ALDO), and endothelin-1 (ET-1). Blood samples (30 ml) were collected at rest and at the end of each one minute step of the exercise test. Plasma concentrations of hormones were measured using radioimmunoassay kits. There were no differences (P > 0.05) between old vs. young mares for resting PRA (2.2 +/- 0.3 vs. 1.5 +/- 0.3 ng/ml/h), or the plasma concentrations of ANP (10.0 +/- 0.9 vs. 10.7 +/- 0.6 pg/ml); AVP (0.7 + 0.7 vs. 1.4 +/- 0.4 pg/ml); ALDO (39.2 +/- 10.3 vs. 22.7 +/- 4.6 pg/ml); or ET-1 (0.23 +/- 0.04 vs. 0.18 +/- 0.03 pg/ml). Exercise significantly increased PRA and the concentrations of ANP, AVP, and ALDO in both groups of horses; however, ET-1 was not altered (P > 0.05) by exercise in either group. There were differences (P < 0.05) between means obtained from the old and young groups for PRA (5.4 +/- 0.6 vs. 3.9 +/- 0.8 ng/ml/h and the concentrations of ANP (14.5 +/- 2.3 vs. 26.5 +/- 9.0 pg/ml), AVP (13.6 +/- 0.3 vs. 26.1 +/- 13.9 pg/ml, and ALDO (76.8 +/- 22.0 vs. 41.5 +/- 4.9 pg/ml) measured in samples obtained at the speed eliciting VO2max. These data suggest that older horses have an age-altered endocrine response to exercise.